Human Molecular Genetics Program, Children’s Memorial Research Center, 2300 Children's Plaza, PO Box 211, Chicago, IL 60614, USA.
Hum Mol Genet. 2010 Oct 15;19(20):3906-18. doi: 10.1093/hmg/ddq330. Epub 2010 Aug 6.
Proximal spinal muscular atrophy (SMA) is the leading genetic cause of infant mortality. Traditionally, SMA has been described as a motor neuron disease; however, there is a growing body of evidence that arrhythmia and/or cardiomyopathy may present in SMA patients at an increased frequency. Here, we ask whether SMA model mice possess such phenotypes. We find SMA mice suffer from severe bradyarrhythmia characterized by progressive heart block and impaired ventricular depolarization. Echocardiography further confirms functional cardiac deficits in SMA mice. Additional investigations show evidence of both sympathetic innervation defects and dilated cardiomyopathy at late stages of disease. Based upon these data, we propose a model in which decreased sympathetic innervation causes autonomic imbalance. Such imbalance would be characterized by a relative increase in the level of vagal tone controlling heart rate, which is consistent with bradyarrhythmia and progressive heart block. Finally, treatment with the histone deacetylase inhibitor trichostatin A, a drug known to benefit phenotypes of SMA model mice, produces prolonged maturation of the SMA heartbeat and an increase in cardiac size. Treated mice maintain measures of motor function throughout extended survival though they ultimately reach death endpoints in association with a progression of bradyarrhythmia. These data represent the novel identification of cardiac arrhythmia as an early and progressive feature of murine SMA while providing several new, quantitative indices of mouse health. Together with clinical cases that report similar symptoms, this reveals a new area of investigation that will be important to address as we move SMA therapeutics towards clinical success.
脊髓性肌萎缩症(SMA)是导致婴儿死亡的主要遗传原因。传统上,SMA 被描述为运动神经元疾病;然而,越来越多的证据表明,心律失常和/或心肌病在 SMA 患者中可能以更高的频率出现。在这里,我们询问 SMA 模型小鼠是否具有这种表型。我们发现 SMA 小鼠患有严重的心动过缓,表现为进行性心脏传导阻滞和心室去极化受损。超声心动图进一步证实了 SMA 小鼠的心脏功能缺陷。进一步的研究表明,在疾病的晚期,存在交感神经支配缺陷和扩张型心肌病的证据。基于这些数据,我们提出了一个模型,即交感神经支配减少导致自主神经失衡。这种失衡的特征是控制心率的迷走神经张力相对增加,这与心动过缓和进行性心脏传导阻滞一致。最后,用组蛋白去乙酰化酶抑制剂 Trichostatin A 进行治疗,这种药物已知能改善 SMA 模型小鼠的表型,可使 SMA 心跳的成熟时间延长,并增加心脏大小。接受治疗的小鼠在延长的存活期内保持运动功能的测量,但它们最终会因心动过缓和进行性心律失常的进展而达到死亡终点。这些数据代表了心脏心律失常作为小鼠 SMA 的早期和进行性特征的新发现,同时提供了几个新的、定量的小鼠健康指标。结合报告类似症状的临床病例,这揭示了一个新的研究领域,随着我们将 SMA 治疗方法推向临床成功,这将是一个重要的研究方向。